

# World Journal of *Diabetes*

*World J Diabetes* 2022 September 15; 13(9): 668-801



## REVIEW

- 668 Nonalcoholic fatty liver disease and diabetes  
*Bellini MI, Urciuoli I, Del Gaudio G, Polti G, Iannetti G, Gangitano E, Lori E, Lubrano C, Cantisani V, Sorrenti S, D'Andrea V*
- 683 A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena  
*Quentin V, Singh M, Nguyen LS*
- 696 Evolving spectrum of diabetic wound: Mechanistic insights and therapeutic targets  
*Chakraborty R, Borah P, Dutta PP, Sen S*

## MINIREVIEWS

- 717 Potential role of *Limosilactobacillus fermentum* as a probiotic with anti-diabetic properties: A review  
*Lacerda DC, Trindade da Costa PC, Pontes PB, Carneiro dos Santos LA, Cruz Neto JPR, Silva Luis CC, de Sousa Brito VP, de Brito Alves JL*
- 729 COVID-19 associated diabetes mellitus: A review  
*Gavkare AM, Nanaware N, Rayate AS, Mumbre S, Nagoba BS*
- 738 Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy  
*Vasilev G, Kabakchieva P, Miteva D, Batselova H, Velikova T*

## ORIGINAL ARTICLE

## Basic Study

- 752 Hyperglycemia and reduced adiposity of streptozotocin-induced diabetic mice are not alleviated by oral benzylamine supplementation  
*Carpéné C, Stiliyanov Atanasov K, Les F, Mercader Barcelo J*
- 765 Role of insulin in pancreatic microcirculatory oxygen profile and bioenergetics  
*Li BW, Li Y, Zhang X, Fu SJ, Wang B, Zhang XY, Liu XT, Wang Q, Li AL, Liu MM*

## Retrospective Study

- 776 Relationship between age of pregnant women with gestational diabetes mellitus and mode of delivery and neonatal Apgar score  
*Gao L, Chen CR, Wang F, Ji Q, Chen KN, Yang Y, Liu HW*

## SCIENTOMETRICS

- 786 Mapping the global research landscape on insulin resistance: Visualization and bibliometric analysis  
*Zyoud SH, Shakhshir M, Koni A, Abushanab AS, Shahwan M, Jairoun AA, Al Subu R, Abu Taha A, Al-Jabi SW*

**LETTER TO THE EDITOR**

- 799** Different nutrient compositions in diet and taking hypoglycemic drugs can modulate gut microbial flora  
*Lin ZJ, Zhang QW, Yu XL, Zhou B, Liu CW, He LP*

**ABOUT COVER**

Peer Reviewer of *World Journal of Diabetes*, Nahlah Elkudssiah Ismail, BPharm (Hons), PhD, Professor, Department of Pharmacy, MAHSA University, Kuala Lumpur 42610, Malaysia. elkudssiah77@yahoo.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJD* mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

**INDEXING/ABSTRACTING**

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJD* as 4.560; IF without journal self cites: 4.450; 5-year IF: 5.370; Journal Citation Indicator: 0.62; Ranking: 62 among 146 journals in endocrinology and metabolism; and Quartile category: Q2.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jia-Ping Yan*.

**NAME OF JOURNAL**

*World Journal of Diabetes*

**ISSN**

ISSN 1948-9358 (online)

**LAUNCH DATE**

June 15, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Lu Cai, Md. Shahidul Islam, Jian-Bo Xiao, Michael Horowitz

**EDITORIAL BOARD MEMBERS**

<https://www.wjnet.com/1948-9358/editorialboard.htm>

**PUBLICATION DATE**

September 15, 2022

**COPYRIGHT**

© 2022 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Different nutrient compositions in diet and taking hypoglycemic drugs can modulate gut microbial flora

Zi-Jun Lin, Qiong-Wen Zhang, Xiao-Lan Yu, Bo Zhou, Chang-Wei Liu, Lian-Ping He

**Specialty type:** Endocrinology and metabolism

**Provenance and peer review:**

Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Alkhatib AJ, Jordan; Eseadi C, Nigeria; Xu PF, United States

**Received:** May 24, 2022

**Peer-review started:** May 24, 2022

**First decision:** July 14, 2022

**Revised:** July 22, 2022

**Accepted:** August 16, 2022

**Article in press:** August 16, 2022

**Published online:** September 15, 2022



**Zi-Jun Lin, Qiong-Wen Zhang, Xiao-Lan Yu, Bo Zhou, Lian-Ping He**, School of Medicine, Taizhou University, Jiaojiang 318000, Zhejiang Province, China

**Chang-Wei Liu**, Children's Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China

**Corresponding author:** Chang-Wei Liu, MM, Doctor, Children's Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Nanjing 210008, Jiangsu Province, China.

[liuchangwei07@163.com](mailto:liuchangwei07@163.com)

### Abstract

The diet structure of diabetic patients is different from that of normal people. Diabetic patients also need to take hypoglycemic drugs to regulate blood sugar. Both dieting and drugs affect the gut microbiota of diabetic patients. In this letter, we discuss that different dietary patterns and the use of hypoglycemic agents may have an impact on changes in gut microbiota in diabetic patients.

**Key Words:** Diabetic patients; Gut microbiota; Hypoglycemic drugs

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Changes in diet can lead to changes in the composition of gut microbiota in diabetic patients. On the other hand, taking hypoglycemic drugs can also change the gut microbiota. Therefore, it is necessary to consider the dietary structure and the use of hypoglycemic drugs in the study of changes in the intestinal flora of patients with diabetes.

**Citation:** Lin ZJ, Zhang QW, Yu XL, Zhou B, Liu CW, He LP. Different nutrient compositions in diet and taking hypoglycemic drugs can modulate gut microbial flora. *World J Diabetes* 2022; 13(9): 799-801

**URL:** <https://www.wjgnet.com/1948-9358/full/v13/i9/799.htm>

**DOI:** <https://dx.doi.org/10.4239/wjd.v13.i9.799>

## TO THE EDITOR

Diabetes mellitus (DM) is one of important risk factor for population health in the twenty-first century worldwide. It is of great significance to explore the lifestyle intervention mode for the prevention and treatment of type 2 diabetes mellitus (T2DM). One study found intermittent hypoxia (IH) was associated with metabolic diseases including as obesity and obstructive sleep apnea-hypopnea syndrome (OSAHS)[1]. IH may be involved in selective alterations of the gut microbiota of T2DM patients with OSAHS. Similarly, changes in gut microbiota can affect the development of T2DM.

Gut microbiota is known to change with diet. Especially when someone suffering from T2DM, doctors often recommend dietary changes to curb the progression of the disease. Changes in eating habits can disrupt the balance of gut microbiota when the body's resistance is low[2]. The study by Liu *et al*[3] showed that blood sugar levels in mouse model of T2DM induced by streptozotocin-high-fat diet were changes with gut microbiota. A large number of studies have shown that diet affects the development of diabetes. For example, blackcurrant extract enhanced insulin sensitivity and glucose-stimulated insulin secretion in non-obese type 2 diabetic rats[4]. Therefore, the diet structure will affect the gut microbiota. However, the following questions need to be further clarified in future studies. What nutrition considerations for persons with diabetes that will impact persons? What are the recommendations for persons with diabetes concerning nutrition to be considered? The link between gut microbial, diabetes, nutrition and autoimmunity are important, but still need to be addressed.

In addition, hypoglycemic drugs also affect gut microbiota. In this study, drugs that regulate IH have an effect on the balance of gut microbiota. We strongly agree with this view. However, when taking drugs to regulate IH, hypoglycemic drugs are also used. Therefore, hypoglycemic drugs also have an impact on the balance of gut microbiota. For some patients who require combination therapy to treat diabetes and complications of diabetes, especially after combination therapy with antibiotics and hypoglycemic drugs, the impact on the intestinal flora is significant[5]. Clinically, metformin is widely used in the treatment of T2DM. Studies have shown that gut microbiota is an active site of metformin. The gut is a potential target of metformin. Metformin induce butyrate and propionate involving glucose homeostasis[6]. When diabetics take metformin, the gut microbiota will definitely change. Studies have also shown that treating diabetic mice with oleuropein (OP) is also treated by modulating the gut microbiota. The OP could decrease fasting blood glucose levels and improve glucose tolerance[7]. Hypoglycemic drugs are also taken when taking drugs that regulate IH, so hypoglycemic drugs will also affect the intestinal flora of patients with IH. It is common for IH patients to take hypoglycemic drugs, so the regulation of hypoglycemic drugs on gut microbiota also needs to be discussed.

On the other hand, IH may be associated with changes in gut microbiota, and it is possible that changes in gut microbiota led to IH. In the clinical setting, the effective treatment for IH is usually oxygen therapy. Thus, we can use oxygen inhalation to intervene in changes in gut microbiota. By conducting oxygen supply experiments, the relationship between IH and gut microbiota can be further reflected, which makes the research results more convincing.

The diet structure of diabetic patients is different from that of normal people. Diabetic patients also need to take hypoglycemic drugs to regulate blood sugar. Both dietary structure of patients with diabetes and hypoglycemic drugs taken by the patients with diabetes can alter the gut microbiota of the patients. Therefore, the influence of diet and drugs on the gut microbiota cannot be ignored.

## FOOTNOTES

**Author contributions:** He LP and Liu CW contributed to the conception of research; Zhang QW, Lin ZJ and Zhou B wrote the manuscript; Zhang QW, Lin ZJ and Yu XL contributed to the revision of the manuscript.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Zi-Jun Lin 0000-0003-1478-3440; Qiong-Wen Zhang 0000-0002-4811-1821; Xiao-Lan Yu 0000-0003-0503-8940; Bo Zhou 0000-0002-2141-4523; Chang-Wei Liu 0000-0002-7590-5176; Lian-Ping He 0000-0002-9627-5599.

**S-Editor:** Fan JR

**L-Editor:** A

**P-Editor:** Fan JR

## REFERENCES

- 1 **Tang SS**, Liang CH, Liu YL, Wei W, Deng XR, Shi XY, Wang LM, Zhang LJ, Yuan HJ. Intermittent hypoxia is involved in gut microbial dysbiosis in type 2 diabetes mellitus and obstructive sleep apnea-hypopnea syndrome. *World J Gastroenterol* 2022; **28**: 2320-2333 [PMID: [35800187](#) DOI: [10.3748/wjg.v28.i21.2320](#)]
- 2 **Song M**, Chan AT, Sun J. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. *Gastroenterology* 2020; **158**: 322-340 [PMID: [31586566](#) DOI: [10.1053/j.gastro.2019.06.048](#)]
- 3 **Liu S**, Qin P, Wang J. High-Fat Diet Alters the Intestinal Microbiota in Streptozotocin-Induced Type 2 Diabetic Mice. *Microorganisms* 2019; **7** [PMID: [31208113](#) DOI: [10.3390/microorganisms7060176](#)]
- 4 **Yang HJ**, Zhang T, Wu XG, Kim MJ, Kim YH, Yang ES, Yoon YS, Park S. Aqueous Blackcurrant Extract Improves Insulin Sensitivity and Secretion and Modulates the Gut Microbiome in Non-Obese Type 2 Diabetic Rats. *Antioxidants (Basel)* 2021; **10** [PMID: [34068659](#) DOI: [10.3390/antiox10050756](#)]
- 5 **Zarrinpar A**, Chaix A, Xu ZZ, Chang MW, Marotz CA, Saghatelian A, Knight R, Panda S. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. *Nat Commun* 2018; **9**: 2872 [PMID: [30030441](#) DOI: [10.1038/s41467-018-05336-9](#)]
- 6 **Wu H**, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernández-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat Med* 2017; **23**: 850-858 [PMID: [28530702](#) DOI: [10.1038/nm.4345](#)]
- 7 **Zheng S**, Wang Y, Fang J, Geng R, Li M, Zhao Y, Kang SG, Huang K, Tong T. Oleuropein Ameliorates Advanced Stage of Type 2 Diabetes in *db/db* Mice by Regulating Gut Microbiota. *Nutrients* 2021; **13** [PMID: [34206641](#) DOI: [10.3390/nu13072131](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

